StemBANCC

The project

Currently, many drugs fail relatively late in the drug development process because the tests used in the earlier stages of drug development simply do not reflect what happens in real life when the drug is administered in patients. This is partly because these early tests rely heavily on animal cells, and when human cells are used, they have often been extensively modified to survive in culture and so no longer behave naturally. Those working in drug research and development therefore urgently need a well-characterized and renewable supply of cells that more accurately mimic what happens in the human body. The main aim of the StemBANCC project is to generate and characterise high quality human induced pluripotent stem (iPS) cell lines from 500 subjects that can be used by researchers to study a range of diseases, including diabetes and dementia, and test for drug efficacy and safety. The cell lines will help to improve and speed up the drug development process, and ensure that patients benefit from more effective and safer drugs.

Contributions

METO was involved in work packages 5 (modelling) and 10 (toxicity testing)

Publications

Datta S, Gayraud G, Leclerc E, Bois F. 2017. Graph_sampler: a simple tool for fully Bayesian analyses of DAG-models. Computational statistics. Volume 32, Issue 2, pp 691-716.

Elias Zgheib, Camille Bechaux, Amelie Crepet, Enrico Mombelli, Frederic Y. Bois. 2017. High-throughput methods for toxicology and health risk assessment. Environnement, Risques & Santé. Volume 16, Issue 1, pp 44-58.

Bois FY., Gayraud G., 2015, Probabilistic Generation of Random Networks Taking into Account Information on Motifs Occurrence. Journal of Computational Biology Volume: 22 Issue: 1 Pages: 25-36.